Introduction
============

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an important cause of ventricular arrhythmias and sudden cardiac death, especially in the young and in athletes (Marcus et al., [@B22]; Thiene et al., [@B36]; Basso et al., [@B2]). Mutations in one or more genes encoding desmosomal proteins are found in ∼50% of patients (McKoy et al., [@B23]; Rampazzo et al., [@B28]; Gerull et al., [@B12]; Pilichou et al., [@B26]; Syrris et al., [@B34]). Desmosomes are highly conserved structures that, together with adherens junctions and gap junctions, connect cardiac myocytes end to end at the level of the intercalated disks and thereby play a crucial role in maintaining proper myocardial function (Delmar and McKenna, [@B6]). Recent findings indicating the presence of mixed type junctions (the area composite; Franke et al., [@B8]) and crosstalk between protein complexes pertaining to the different types of junctions (Delmar, [@B5]; Meadows and Isom, [@B24]; Saffitz, [@B30]; Tavora et al., [@B35]; Li and Radice, [@B20]; Sato et al., [@B31]) have markedly changed the perception of the intercalated disk. Altered junctional organization, as the result of mutations, is thought to lead to myocardial damage and replacement fibrosis, the classical histopathologic pattern of ARVC (Basso et al., [@B2]). In advanced stages of the disease, focal scars cause electrical isolation of cardiomyocytes within non-conducting fibrous tissue, resulting in slow conduction and delayed activation, thus forming the substrate for re-entrant circuits and ventricular electrical instability. Over the years several mouse models have been developed to investigate the mechanisms of disease development in ARVC (Pilichou et al., [@B25]), focusing on four of the desmosomal proteins: Plakophilin-2, Plakoglobin (γ-catenin), Desmoplakin, and Desmoglein 2. All four will be discussed in detail below; an overview of all the models is given in Table [1](#T1){ref-type="table"}.

###### 

**Arrhythmogenic right ventricular cardiomyopathy mouse models**.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr         Protein                 Gene       Mutation/targeted exons   Model type                                         Reference
  ---------- ----------------------- ---------- ------------------------- -------------------------------------------------- ------------------------------------------------------------------------
  Pk1        Plakophilin-2           *Pkp2*     Exon 1-intron 1           Targeted deletion                                  Grossmann et al. ([@B14])

  Pk2        Plakophilin-2           *Pkp2*     Exon 1-intron 1           Targeted deletion                                  Grossmann et al. ([@B14])

  Pg1        Plakoglobin             *Jup*      Exon 2--5                 Targeted deletion                                  Bierkamp et al. ([@B4])

  Pg2--Pg4   Plakoglobin             *Jup*      Exon 34                   Targeted deletion                                  Ruiz et al. ([@B29]), Kirchhof et al. ([@B17]), Fabritz et al. ([@B7])

  Pg5        Plakoglobin             *Jup*      Exon 2--3                 Inducible deletion; αMHCcre induced                Li et al. ([@B19])

  Pg6        Plakoglobin β-catenin   *Jup*\     Exon 2--3\                αMHC/MerCreMer tamoxifen induced double deletion   Swope et al. ([@B33])
                                     *Ctnnb1*   Exon 2--5                                                                    

  Pg7        Plakoglobin             *Jup*      Wild type                 Flag tagged transgene                              Lombardi et al. ([@B21])

  Pg8        Plakoglobin             *Jup*      23654Δ2                   Transgene                                          Lombardi et al. ([@B21])

                                                Truncated                                                                    

  Dp1        Desmoplakin             *Dsp*      Δ281--473                 Targeted deletion with extra-embryonic rescue      Gallicano et al. ([@B9])

  Dp2        Desmoplakin             *Dsp*      Exon 2                    Inducible deletion; αMHCcre induced                Garcia-Gras et al. ([@B11]), Gomes et al. ([@B13])

  Dp3        Desmoplakin             *Dsp*      Wild type                 Flag tagged transgene, αMHC promoter               Yang et al. ([@B37])

  Dp4        Desmoplakin             *Dsp*      R2834H                    Flag tagged transgene, αMHC promoter               Yang et al. ([@B37])

  Dp5        Desmoplakin             *Dsp*      Q90R                      Flag tagged transgene, αMHC promoter               Yang et al. ([@B37])

  Dp6        Desmoplakin             *Dsp*      V30M                      Flag tagged transgene, αMHC promoter               Yang et al. ([@B37])

  Dg1        Desmoglein 2            *Dsg2*     Wild type                 Flag tagged transgene, αMHC promoter               Pilichou et al. ([@B27])

  Dg2        Desmoglein 2            *Dsg2*     N271S                     Flag tagged transgene, αMHC promoter               Pilichou et al. ([@B27])

  Dg3        Desmoglein 3            *Dsg2*     Exon 4--6                 Targeted deletion                                  Krusche et al. ([@B18]), Kant et al. ([@B15])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plakophilin-2 Targeted Deletion
===============================

The first mouse model described that addresses disruption of one of the desmosomal proteins is the study by Grossmann et al. ([@B14]) that describes the targeted deletion of plakophilin-2. The heterozygous mice carrying one wild type copy of plakophilin-2 were completely viable without any cardiac phenotype. Mouse homozygous for the deletion (Pkp2^−/−^) died during embryonic development around day 11 post fertilization. Embryos at day 10.5 appeared pale with blood aggregates in the interperitoneal cavity indicating the presence of small holes in the endothelial layers lining the heart and vessels. It would be interesting to see if the Pkp2^±^ mice develop an ARVC like phenotype upon exercise.

Plakoglobin Targeted Deletion and Overexpression Models
=======================================================

The first papers on mouse models involving a desmosomal protein described the targeted deletion of *Plakoglobin* (*Pg*) by two independent groups in 1996 (models Pg1 and Pg2; Bierkamp et al., [@B4]; Ruiz et al., [@B29]). Homozygous targeted deletion of *Plakoglobin* leads to embryonic lethality between embryonic day 9.5 and 16 due to cardiac malformations: thin cardiac walls and less trabeculation and frequent burst of the epicardial wall; in addition mice showed a blistering skin phenotype. Heterozygous animals appeared healthy and fertile. However, closer inspection of these mice (model Pg2) after the link between ARVC and desmosomal proteins had become clear showed that Pg^±^ mice at 10 months after birth had enlarged right ventricles, increased spontaneous ventricular arrhythmias and right ventricular conduction slowing. No replacement fibrosis and remodeling of the junctions was observed, Cx43 localization and distribution were normal on immunofluorescence microscopy. All observed changes were exacerbated and expedited when mice were subjected to exercise training (model Pg3; Kirchhof et al., [@B17]). Load reducing therapy is able to prevent these symptoms of ARVC in Pg^±^ mice (model Pg4; Fabritz et al., [@B7]).

To circumvent the problem of neonatal lethality, a cardiac specific targeted deletion of Pg was developed under the control of αMHCcre. *Pg^f/f^* αMHCcre (model Pg5) mice have ∼30% of the WT protein as measured by Western blot, no Pg was detectable by immunofluorescence on cardiac sections. Phenotypically these mice largely recapitulate the human ARVC phenotype: cardiac sudden death, progressive dilation, and fibrosis in the cardiac walls (both in the left and the right ventricle) from 2 month onward. No cardiac fat deposition was observed. With transmission electron microscopy the structure of the desmosomes seemed to be disrupted: other desmosomal proteins (e.g., Dsg2) appeared to be absent from the intercalated disk (Li et al., [@B19]). Cell death in the *Pg^f/f^* αMHCcre mice was at least partially through myocyte apoptosis in addition to myocyte necrosis in contrast to mice overexpressing N271S-Dsg2, which mainly showed myocyte necrosis (see below; Pilichou et al., [@B26]; Li et al., [@B19]). Interestingly, increased β-catenin staining was observed at the intercalated disk suggesting partial rescue by this close relative of Pg (γ-catenin). To test whether the lack of fast spontaneous death in these mice (model Pg5) was due to a partial rescue by β-catenin, double-targeted mice were created, carrying both a floxed Pg gene and a floxed β-catenin locus (*Pg^f/f^*; β*-catenin^f/f^*). Crossing with αMHC/MerCreMer mice and subsequent tamoxifen injections effected specific targeted deletion. Double-targeted mice (model Pg6) showed a strong arrhythmogenic phenotype, with 100% of the double-targeted animals dying of sudden cardiac death between 3 and 5 months after tamoxifen injections. In contrast to either single targeted deletion and wild type littermates of which 4--9% died within 6 months of tamoxifen injection (Swope et al., [@B33]).

Two lines overexpressing wild type (model Pg7) and mutant (model Pg8) Pg were generated (Lombardi et al., [@B21]); both showed similar levels of increased incidence of sudden cardiac death, an indication that even moderate levels of overexpression of *Pg* disturb the balance of the mechanical interaction and signaling functions of *Pg* independent of the introduced truncating mutation.

Desmoplakin Targeted Deletion and Overexpression Models
=======================================================

*Desmoplakin* (*Dsp*) targeted deletion mice *Dsp*^−/−^ die at embryonic day 6.5 of malformations in the extra-embryonic tissue before assessment of a cardiac phenotype is possible (Gallicano et al., [@B10]). To overcome this problem the extra-embryonic phenotype was rescued by tetraploid aggregation (model Dp1). The resulting embryos die around embryonic day E11. At E10 they show severe cardiac malformation although desmosomal-like structures appear to be present by transmission electron microscopy. As these mice die well before birth they are obviously unsuitable as a proper model for ARVC (Gallicano et al., [@B9]). The embryonic lethality of the *Dsp*^−/−^ mice is partially circumvented in the cardiac specific, αMHCcre induced, targeted deletion of *Dsp* (model Dp2; Garcia-Gras et al., [@B11]). The homozygous cardiac specific deletion of *Dsp* leads to embryonic growth arrest at day E10--E12 with embryos that appeared very pale, with no circulating red blood cells in organs. The heart was poorly formed with no chamber specification, 80% of *Dsp*^−/−^ mice did not survive until delivery. Mice that did survive the embryonic period died within 6 weeks after birth. Heterozygous *Dsp*^±^ mice developed normally, however adult *Dsp*^±^ mice had thin ventricular walls, increased left ventricular diameters and reduced left ventricular ejection fraction. Spontaneous arrhythmias were observed on surface ECG and 4/5 mice developed ventricular arrhythmias after a single ventricular extra stimulus.

A more detailed study of these *Dsp*^±^ mice at earlier stages of disease development, when no abnormalities at the surface ECGs could be detected and no evidence of replacement fibrosis could yet be found, showed a significant increase in the activation time and inducible arrhythmias in Langendorff perfused hearts. These results indicate the presence of electrophysiological abnormalities before the onset of overt structural changes (Gomes et al., [@B13]). However, no electron microscopy was done to exclude the presence of disrupted desmosomes at the ultrastructural level.

Transgenic mice with cardiac overexpression of flag tagged human *Dsp* cDNA both wild type (WT-Tg, model Dp3) and with a C-terminal mutation (R2834H-Tg, model Dp4) were generated by Yang et al. ([@B37]). Overexpression of *Dsp* with N-terminal mutations, e.g., V30M (model Dp5) and Q90R (model Dp6) led to embryonic lethality after embryonic day 13.5 due to reduced ventricular wall thickness and ventricular dilatation. R2834H-Tg mice had an increased heart weight/body weight ratio compared to both wild type littermates and Wt-Tg mice. R2834H-Tg hearts showed increased apoptosis and fibrosis along with reduced ventricular function and dilatation of both right and left ventricles. Co-immunoprecipitation indicated the disruption of the interaction between Dsp and Pg. at the ultrastructural level widening of the intercalated disk was observed in Dp4 mice.

Desmoglein Overexpression Models
================================

Transgenic mice with cardiac overexpression of flag tagged Dsg2 both wild type (Tg-WT, model Dg1) and N271S-Dsg2 mutant (Tg-NS, model Dg2) were generated; the murine N271S mutation is the mouse homolog of the human ARVC mutation DSG2--N266S. While mice overexpressing of wild type *Dsg2* were indistinguishable from their wild type littermates at 2 months of age, Tg-Ns mice developed spontaneous ventricular arrhythmias, conduction slowing, ventricular dilatation and aneurysms, and replacement fibrosis, leading to sudden cardiac death from a less than 2 weeks of age. The disease process was triggered by myocyte necrosis followed by calcification and fibrous tissue replacement (Pilichou et al., [@B27]). These findings are consistent with the results obtained in mice carrying a targeted deletion in the extracellular adhesion domain of Dsg2 (model Dg3). Approximately 30% of the mice homozygous for the mutation survived embryonic development. These mice develop left and right ventricular dilatation, fibrosis, calcification, and spontaneous death similar to the Tg-NS mice (Krusche et al., [@B18]). Detailed investigation of this model by transmission electron microscopy revealed a widening of the intercellular space at the intercalated disk and loss of desmosomal structure close to macroscopically visible lesions of the heart (Kant et al., [@B15]).

Discussion and Conclusion
=========================

The diverse mouse models discussed here recapitulate ARVC disease phenotype and have led to several new insights in the etiology of the cardiac phenotype in ARVC patients. The initial targeted deletion of single desmosomal genes, although embryonically lethal, gave fundamental insights in effects of desmosomal gene dysfunction on cardiac function. All the different models surviving embryonic development, recapitulate the human phenotype in the sense of the arrhythmogenicity, replacement fibrosis, and calcification. None of the models show the clear fatty infiltrations seen in human, this is most likely a reflection of the different composition of the extracellular matrix and non-cardiomyocytes interstitial cells in the wild type murine heart, which lacks a significant adipocyte population (Pilichou et al., [@B27]). In all described mouse models that survive the embryonic period, the disease process is triggered by cardiac cell death upon cardiac stress after birth. However, they are inconsistent considering the type of cell death occurring, with necrosis being the prominent feature in the Desmoglein 2 models (Dg2 and Dg3) and apoptosis (in addition to necrosis) in the plakoglobin models (Pg5 and Pg6). As a consequence of the myocyte death, calcification, and replacement fibrosis occurs leading to reduced cardiac function and ventricular dilatation. This scar formation also provides a substrate for the arrhythmogenic phenotype seen both in human patients and the ARVC mouse models. The study by Fabritz et al. ([@B7]) shows the positive effect of load reducing therapy on disease progression, clearly underwriting the current disease management strategy of discouraging strenuous physical exercise in patients.

Knowledge of the early disease stages would help in designing more effective treatments (Basso et al., [@B1]). However, the earliest phase of the disease remains thus far elusive due to the early postnatal severe pathogenicity of the phenotype, precluding the effective dissection of the first pathological changes in the affected hearts. The recent study of Gomes et al. suggests the presence of an electrophysiological disturbance before the development of overt cardiomyopathic changes (Kaplan et al., [@B16]; Gomes et al., [@B13]). The proposal of electrical disturbances at this early stage of the disease is an attractive one in the light of the recent data showing cross talk between the mechanical junctions, the gap junctions and the Na^+^ channel complex (Sato et al., [@B32], [@B31]) and the presence of arrhythmias early in the disease process in humans (Bauce et al., [@B3]). Unfortunately, this study fails to examine the desmosomal structure at this specific time point; it would be interesting to see whether there are ultrastructural changes present that cause the observed electrical changes. Furthermore, the electrophysiological data presented lacks sufficient detail (e.g., Na^+^-current and action potential measurements) to be able to draw definitive conclusions on the nature of the observed early electrical disturbances.

In conclusion, since the discovery a little over a decade ago that the cause of ARVC lies within the cardiac desmosomal complex and its associated proteins, a wealth of knowledge has been build up on the etiology of the disease. The use of the murine transgenic and targeted models has played a pivotal role in this process. The quest to answer the many remaining questions on the first stages of the disease and the search for a good treatment will continue during the next decade, the developed mouse models will undoubtedly play an important role in this process.
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